Distribution at the Crossroads
Whether in drugs or med/surg supply, the willingness of a cost-constrained customer to place greater value on an efficient distribution system than on the features and benefits of an individual product or piece of technology has subtly shifted the power within the supply chain.
You may also be interested in...
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.
Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.